We are live on ! Find out more
CTMX icon

CytomX Therapeutics
CTMX

74 hedge funds and large institutions have $61.9M invested in CytomX Therapeutics in 2024 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 29 increasing their positions, 24 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more repeat investments, than reductions

Existing positions increased: 29 | Existing positions reduced: 24

0.74% less ownership

Funds ownership: 65.79% → 65.05% (-0.74%)

16% less funds holding

Funds holding: 88 → 74 (-14)

30% less call options, than puts

Call options by funds: $30K | Put options by funds: $43K

36% less capital invested

Capital invested by funds: $97.1M → $61.9M (-$35.3M)

52% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 27

Holders
74
Holders Change
-14
Holders Change %
-15.91%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
29
Reduced
24
Closed
27
Calls
$30K
Puts
$43K
Net Calls
-$13K
Net Calls Change
-$356K

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$12.5M
2
TCM
Tang Capital Management
California
+$2.67M
3
RI
RTW Investments
New York
+$2.39M
4
Millennium Management
Millennium Management
New York
+$2.34M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$1.99M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$7.73M
2
SCM
Sio Capital Management
New York
-$3.48M
3
BI
BVF Inc
California
-$2.72M
4
BCM
Bronte Capital Management
Australia
-$1.98M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.81M
Name Holding Trade Value Shares
Change 		Change in
Stake
TCM
1
Tang Capital Management
California
$9.51M +$2.67M +1,341,936 +21%
Janus Henderson Group
2
Janus Henderson Group
United Kingdom
$7.72M +$12.5M +6,301,983 New
BI
3
BVF Inc
California
$6.38M -$2.72M -1,367,340 -21%
Vanguard Group
4
Vanguard Group
Pennsylvania
$5.97M +$69.5K +34,928 +0.7%
Adage Capital Partners
5
Adage Capital Partners
Massachusetts
$3.66M +$1.99M +1,000,000 +50%
Acadian Asset Management
6
Acadian Asset Management
Massachusetts
$3.32M +$75.1K +37,739 +1%
Millennium Management
7
Millennium Management
New York
$2.25M +$2.34M +1,173,775 +175%
LCM
8
Laurion Capital Management
New York
$1.86M +$1.52M +762,200 +100%
Jacobs Levy Equity Management
9
Jacobs Levy Equity Management
New Jersey
$1.84M +$1.95M +977,782 +185%
SSA
10
Schonfeld Strategic Advisors
New York
$1.68M +$201K +100,783 +8%
Assenagon Asset Management
11
Assenagon Asset Management
Luxembourg
$1.51M +$1.66M +833,825 +206%
RI
12
RTW Investments
New York
$1.46M +$2.39M +1,200,002 New
Renaissance Technologies
13
Renaissance Technologies
New York
$1.44M -$99.1K -49,778 -4%
CPC
14
Congress Park Capital
New York
$1.41M +$1.83M +919,420 +393%
SCM
15
Superstring Capital Management
New York
$1.4M +$940K +472,115 +69%
BlackRock
16
BlackRock
New York
$1.39M +$15.6K +7,821 +0.7%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$939K +$32K +16,101 +2%
Two Sigma Investments
18
Two Sigma Investments
New York
$808K +$812K +408,174 +161%
ACM
19
ADAR1 Capital Management
Texas
$698K +$830K +417,170 +269%
Citadel Advisors
20
Citadel Advisors
Florida
$603K +$911K +457,866 +1,245%
SEI Investments
21
SEI Investments
Pennsylvania
$467K +$762K +382,723 New
BCM
22
Bridgeway Capital Management
Texas
$450K -$147K -74,100 -17%
GTC
23
Ghost Tree Capital
New York
$366K -$597K -300,000 -50%
State Street
24
State Street
Massachusetts
$322K -$7.63K -3,833 -1%
FAM
25
Formidable Asset Management
Ohio
$315K -$59.9K -30,100 -10%
1
2 3 4 5

CTMX Hedge Fund Activity: Q2 2024 in Review

74 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in CytomX Therapeutics (CTMX) for Q2 2024, worth a combined $61.9M — down 36% from $97.1M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of CTMX and 13 opened new positions — a net loss of 14 holders — while 24 trimmed existing stakes and 29 added.

The largest buyer was Janus Henderson Group, opening a new position worth an estimated $12.5M. The largest seller was OrbiMed, exiting entirely with an estimated $7.73M sold.

  • 74 institutional investors held CytomX Therapeutics (CTMX) as of Q2 2024, down from 88 in Q1 2024.
  • Funds reported $61.9M of CytomX Therapeutics stock for Q2 2024, down 36% quarter-over-quarter.
  • 13 funds opened new CytomX Therapeutics positions in Q2 2024 and 27 closed out, a net change of -14 holders.
  • The largest CytomX Therapeutics buyer in Q2 2024 was Janus Henderson Group, an estimated $12.5M added.
  • The largest CytomX Therapeutics seller in Q2 2024 was OrbiMed, an estimated $7.73M sold.

Based on aggregated 13F filings for Q2 2024.